Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution-Non Commercial 3.0 Unported Licence

Penicurvularins A and B, macrolides from an ascomycete fungus Alternaria sp.

Peinan Fua, Xi Rena, Qiaoling Wanga, Feng Guoa, Tingnan Zhoub and Zhiyang Lv*a
aSchool of Pharmacy, Jiangsu Food and Pharmaceutical Science College, Huaian 223003, People's Republic of China. E-mail: lvpharm@163.com
bInstitute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, People's Republic of China

Received 25th December 2025 , Accepted 19th January 2026

First published on 6th February 2026


Abstract

Two new macrolides, penicurvularins A and B (1 and 2), and the three known compounds (35) were isolated from cultures of the ascomycete fungus Alternaria sp. Their structures were elucidated primarily by NMR experiments. The absolute configuration of 1 was assigned from electronic circular dichroism calculations. Compounds 1 and 5 are active against aquatic pathogenic bacteria Vibrio alginolyticus and V. harveyi with MIC values ranging from 4 to 8 µg mL−1, while compound 5 is cytotoxic against tumor cell lines Huh7, 786-O, and 5673 with IC50 values of 11.6, 10.7, and 3.5 µM, respectively.


Introduction

Macrolides are a structurally diverse and biologically significant class of natural products characterized by a macrocyclic lactone ring, typically containing 12–16 carbon atoms or more.1 These compounds have been extensively studied for their broad spectrum of biological activities, including antibacterial,2,3 antifungal,4,5 antiparasitic,6 anti-inflammatory7,8 and antitumor9 properties. Since the discovery of erythromycin in the 1950s,10 macrolides have played a pivotal role in pharmaceutical development, particularly in the treatment of infectious diseases.11 Beyond their clinical applications, macrolides have also garnered attention as lead compounds for drug discovery and as probes for investigating cellular processes.12

Curvularin-type polyketides represent another intriguing class of fungal secondary metabolites, characterized by a 12-membered macrocyclic lactone fused to a resorcylic acid moiety.13–15 These compounds, exemplified by curvularin and its analogues, have been reported to exhibit a range of bioactivities. The biosynthesis of curvularins involves iterative type I polyketide synthases (PKSs), and their structural diversity is often attributed to post-PKS modifications such as oxidation and methylation.16 Despite their relatively simple structures compared with other macrolides, curvularins have shown promising potential as chemical scaffolds for bioactive molecule development.15 During our continuous search for new bioactive metabolites from the ascomycete fungus fungi,17–19 a strain of Alternaria sp. isolated from a soil sample collected from the Qinghai-Tibetan plateau, Tibet, People's Republic of China, was grown in a solid-substrate fermentation culture. An ethyl acetate (EtOAc) extract of the culture showed cytotoxic effects towards a small panel of three tumor cell lines. Fractionation of the extract afforded two new macrolides, which we named penicurvularins A and B (1 and 2; Fig. 1), and the three known compounds 5-methoxycurvularin,20 curvularin21 and dehydrocurvularin22 (35; Fig. 1). Details of the isolation, structure elucidation, and bioactivity screening of these compounds are reported herein.


image file: d5ra09998f-f1.tif
Fig. 1 Structures of compounds 15.

Results and discussion

Penicurvularin A (1) was assigned a molecular formula of C22H22O6 (12 degrees of unsaturation) by HRESIMS. Its IR spectrum showed the presence of hydroxyl (3420 cm−1), an ester carbonyl (1715 cm−1) groups. Analysis of its NMR data (Table 1) revealed the presence of two methyl groups, four methylene, one oxymethines, 14 aromatic carbons with six oxygenated (δC 148.4, 150.7, 153.9, 155.3, 156.3 and 157.7) and five protonated, and one carboxylic carbon (δC 171.6). These data accounted for all of the NMR resonances and suggested that 1 was a tetracyclic compound. The 1H–1H COSY NMR data showed three isolated spin-system of C-10−C-11, C-13−C-16 and C-3′−C-4′ (Fig. 2). The HMBC correlations from H-6 to C-4, C-5, C-7, C-8 and C-9, and from H2-2 to C-1, C-3, C-4 and C-8, a 1,2,3,5,6-pentasubstituted phenyl unit fusing at C-3/C-8 was deduced. Correlations from H-10 and H-11 to C-9 and C-12, from H2-13 to C-12, and from H-15 to C-1, plus the chemical shift values for C-9, C-12 and C-15 (δC 148.4, 156.3 and 72.9), established a furan unit fused to the 5-methyl-1,6-dioxacycloundecan-7-one at C-9/C-12. Further correlations from H2-1′ to C-4, C-2′ and C-3′, and from H3-6′ to C-4′ and C-5′, plus the chemical shift values for C-2′ and C-5′ (δC 153.9 and 150.7) lead to the connection of 5-methylfuran-2-yl-methyl moiety to C-1′ via C-4. On the basis of these data, the gross structure of 1 was established as shown.
Table 1 NMR data of 1 and 2
No. 1 2
δCa, type δHb (J in Hz) δCa, type δHb (J in Hz)
a Recorded at 600 MHz.b Recorded at 150 MHz.
1 171.6, qC   174.9, qC  
2 37.7, CH2 3.71, d (14.8) 32.8, CH2 3.96 d (13.5)
    2.84, d (14.8)   3.64 d (13.5)
3 139.5, qC   120.9, qC  
4 117.7, qC   136.4, qC  
5 157.7, qC   152.7, qC  
6 102.1, CH 6.51, s 98.8, CH 6.52, s
7 155.3, qC   148.8, qC  
8 112.3, qC   122.5, qC  
9 148.4, qC   208.4, qC  
10 107.3, CH 6.11, d (3.0) 44.2, CH2 3.12, m
        2.57, m
11 111.0, CH 6.25, d (3.0) 24.6, CH2 1.80, m
        1.36, m
12 156.3, qC   27.9, CH2 1.52, m
        1.21, m
13 26.4, CH2 2.85, m 25.3, CH2 1.51, m
    2.64, m   1.21, m
14 37.2, CH2 2.02, m 31.9, CH2 1.56, m
    1.76, m    
15 72.9, CH 5.10, m 75.6, CH 4.86, m
16 21.4, CH3 1.20, d (6.4) 20.4, CH3 1.24, d (5.8)
1′ 25.6, CH2 4.18, d (16.2)    
    3.88, d (16.2)    
2′ 153.9, qC      
3′ 106.9, CH 5.70, d (2.9)    
4′ 106.9, CH 5.82, d (2.9)    
5′ 150.7, qC      
6′ 13.5, CH3 2.18, s    
5-OCH3     56.2, CH3 3.75, s



image file: d5ra09998f-f2.tif
Fig. 2 Key 1H–1H COSY and HMBC correlations of 1 and 2.

The absolute configuration of 1 was deduced by comparison of the experimental and simulated electronic circular dichroism (ECD) spectra calculated using the time-dependent density functional theory (TDDFT)23 for the (15S)-1 (1a) and (15R)-1 (1b) enantiomers. A systematic conformational analysis for 1a was performed using the OPLS3 molecular mechanics force field followed by reoptimization at the B3LYP/6-311G(d, p) level afforded the lowest energy conformers (Fig. S11). The overall calculated ECD spectra of 1a was then generated according to Boltzmann weighting of its lowest energy conformers by its relative energies (Fig. 3). And the overall calculated ECD spectra of 1b was generated with Specdis1.70 software according to its enantiomer of 1a. The experimental ECD curve of 1 was nearly identical to that calculated for 1a, suggesting the 15S absolute configuration for 1.


image file: d5ra09998f-f3.tif
Fig. 3 Experimental ECD spectrum of 1 in MeOH and the calculated ECD spectra of 1a and 1b.

Penicurvularin B (2) was determined to have a molecular formula of C17H22O6 (7 of unsaturation) based on HRESIMS and the NMR data (Table 1), which is 16 mass units higher than that of 3. Analysis of the 1H and 13C NMR data for 2 revealed the presence of structural features similar to those found in 3, except that H-4 (δH 6.35) were absent. Considering the chemical shift values of C-4 (δC 136.4), the remaining exchangeable proton was assigned as OH-4 by default, which was confirmed by the HMBC correlation from H-2 and H-6 to C-4. Therefore, the gross structure of 2 was established. The ECD spectrum of 2 was nearly identical to that of 3 (Fig. S21), and rotation value of 2 {[a]25D −79.9 (c 0.10, MeOH)} was consistent with the reported one {[a]20D −43.9 (c 0.02, MeOH)},20 indicating that the absolute configuration of 2 was the same as that of 3.

The other known compounds 35 isolated from the crude extract were identified as 5-methoxycurvularin (3),20 curvularin (4),21 dehydrocurvularin (5),22 respectively, by comparison of their NMR and MS data with those reported.

Compounds 15 were tested for cytotoxicity against three human tumor cell lines, Huh7 (hepatocellular carcinoma cells), 786-O (kidney cancer cells), 5673 (bladder cancer cell), compound 5 showed potent cytotoxic effects,24 with IC50 values of 11.6, 10.7 and 3.5 µM, respectively (Table 2). Compounds 15 were aslo evaluated for antibacterial activities against two aquatic bacteria25 Vibrio alginolyticus ATCC 33787, V. harveyi ATCC 33842. Compounds 1 and 5 exhibited inhibitory activities against the aquatic pathogens V. alginolyticus and V. harveyi with MIC values of 4–8 µg mL−1 (Table 3). Previously, curvularin and its derivatives were found to exhibit anti-inflammatory activity and other activities.19,26 Among the compounds tested (compounds 15, Table 2), only compound 5 exhibited cytotoxic activity. It is worth noting that compound 5 has the α,β-unsaturated ketone functional group, but compounds 14 do not have such moiety. Therefore, the α,β-unsaturated ketone in compound 5 might be responsible for cytotoxic activity. The cytotoxic mechanism of action of the α,β-unsaturated carbonyl compounds normally involves Michael type addition.27

Table 2 Cytotoxicity of compounds 15
Compound IC50 a(µM)
Huh7 786-O 5673
a IC50 values were averaged from at least three independent experiments.b No activity was detected at 50 µM.c Positive control.
1 NAb NAb NAb
2 NAb NAb NAb
3 NAb NAb NAb
4 NAb NAb NAb
5 11.6 ± 1.8 10.7 ± 1.2 3.5 ± 0.3
cisplatinc 5.2 ± 0.7 5.3 ± 0.5 4.5 ± 0.5


Table 3 Antibacterial activities of compounds 15 (MIC, µg mL−1)a
Strains Compounds
1 2 3 4 5 Chloramphenicolc
a MIC values were averaged from at least three independent experiments.b No activity was detected at 64 µg mL−1.c Positive control.
V. alginolyticus 4 NAb NAb NAb 4 0.5
V. harveyi 8 NAb NAb NAb 8 1


Experimental

General experimental procedures

Optical rotations were measured on a Rudolph Research Analytical automatic polarimeter, and UV data were recorded on a Shimadzu Biospec-1601 spectrophotometer. CD spectra were recorded on a JASCO J-815 spectropolarimeter (solvent: MeOH; measure range: 400–200 nm; accumulations: 2; cell length: 1 mm; temperature: 25 °C; bandwidth: 1.00 nm; scanning speed: 100 nm min; concentration: 0.1). IR data were recorded using a Nicolet Magna-IR 750 spectrophotometer. 1H and 13C NMR spectra were acquired with Bruker Avance III-600 spectrometers using solvent signals (Acetone-d6: δH 2.05/δC 29.84; CDCl3: δH 7.26/δC 77.16) as references. The HSQC and HMBC experiments were optimized for 145.0 and 8.0 Hz, respectively. ESIMS and HRESIMS data were obtained on an Agilent Accurate-Mass-Q-TOF LC/MS G6550 instrument equipped with an ESI source. HPLC analysis and separation were performed using an Agilent 1260 instrument equipped with a variable-wavelength UV detector.

Fungal material

The culture of Alternaria sp. isolated from a soil sample collected from the Qinghai-Tibetan plateau, Tibet, People's Republic of China, in 2009. The isolate was identified based on morphology and sequence (GenBank Accession No. ON310806) analysis of the ITS region of the rDNA. The fungal strain was cultured on slants of potato dextrose agar (PDA) at 25 °C for 10 days. Agar plugs were cut into small pieces (about 0.5 × 0.5 × 0.5 cm3) under aseptic conditions, and 25 pieces were used to inoculate in five 250 mL Erlenmeyer flasks, each containing 50 mL of media (0.4% glucose, 1% malt extract, and 0.4% yeast extract), and the final pH of the media was adjusted to 6.5 and sterilized by autoclave. Five flasks of the inoculated media were incubated at 25 °C on a rotary shaker at 170 rpm for 5 days to prepare the seed culture. Fermentation was carried out in 40 Fernbach flasks (500 mL) each containing 80 g of rice. Distilled H2O (120 mL) was added to each flask, and the contents were soaked overnight before autoclaving at 15 psi for 30 min. After cooling to room temperature, each flask was inoculated with 5.0 mL of the spore inoculum and incubated at 25 °C for 40 days.

Extraction and isolation

The fermentation material was extracted repeatedly with EtOAc (4 × 4.0 L), and the organic solvent was evaporated to dryness under vacuum to afford 15.3 g of crude extract. The crude extract was fractionated by silica gel vacuum liquid chromatography (VLC) using petroleum ether–CH2Cl2–EtOAc–MeOH gradient elution. The fraction (1.5 g) eluted with 7:3 CH2Cl2–EtOAc was separated by reversed-phase silica gel column chromatography (CC) eluting with a MeOH–H2O gradient. The fraction (258 mg) eluted with 45% MeOH–H2O was further separated by Sephadex LH-20 CC eluting with MeOH, and the resulting subfractions were combined and purified by semipreparative reversed-phase (RP) HPLC (Agilent Zorbax SB-C18 column; 5 mm; 9.4 × 250 mm; 48% MeOH in H2O for 35 min; 3 mL min−1) to afford 5 (20.5 mg, tR 18.5 min) and 4 (100.2 mg, tR 31.6 min). The fraction (1.3 g) eluted with 3:2.

CH2Cl2–EtOAc was separated by reversed-phase silica gel CC eluting with a MeOH–H2O gradient. The fraction (100 mg) eluted with 60% MeOH–H2O was further separated by Sephadex LH-20 CC eluting with MeOH, and the resulting subfractions were combined and purified by semipreparative RP HPLC (Agilent Zorbax SB-C18 column; 5 mm; 9.4 × 250 mm; 65% MeOH in H2O for 35 min; 3 mL per min) to afford 2 (4.5 mg, tR 10.0 min), 3 (2.1 mg, tR 11.5 min), and 1 (3.5 mg, tR 30.5 min).

Penicurvularin A (1). white amorphous powder; [α]25D +16.0 (c 0.1, MeOH); UV (MeOH) λmax (log ε) 204 (3.50), 290 (3.68) nm; CD (c 3.3 × 10−4 M, MeOH) λmaxε) 226 (−2.73), 253 (+1.19), 294 (+0.40) nm; IR (neat) νmax 3420, 2933, 1715, 1608, 1250, 1164, 1053 cm−1; 1H and 13C NMR data see Table 1; HMBC data (Acetone-d6, 600 MHz) H2-2 → C-1, 3, 4, 8; H-6 → C-4, 5, 7, 8, 9; H-10 → C- 9, 12; H-11 → C-9, 12; H-13 → C- 12; H-15 → C-1; H3-16 → C-14, 15; H2-1′ → C-3, 4, 5, 2′ 3′; H-3′ → C-2′, 4′, 5′; H-4′ → C-2′, 3′, 5′; H3-6′ → C-4′, 5′; HRESIMS m/z 383.1483 [M + H]+ (calcd for C22H23O6, 383.1489).

Penicurvularin B (2). white amorphous powder; [α]25D −79.9 (c 0.1, MeOH); UV (MeOH) λmax (log ε) 208 (3.91), 238 (3.75), 316 (3.43) nm; CD (c 2.0 × 10−4 M, MeOH) λmaxε) 216 (−2.35), 243 (+3.61), 290 (−10.71) 358 (−1.99) nm; IR (neat) νmax 3361, 2941, 1697, 1596, 1271, 1127, 1021 cm−1; 1H and 13C NMR data see Table 1; HMBC data (CDCl3, 600 MHz) H2-2 → C-1, 3, 4, 8; H-6 → C-4, 5, 7, 8, 9; H2-11 → C-9; H2-12 → C-10; H2-13 → C-14; H2-14 → C-12, 13, 16; H3-16 → C-14, 15; OCH3-5 → C-5; HRESIMS m/z 323.1485 [M + H]+ (calcd for C17H23O6, 323.1489).

Computational details

Conformational analyses for 1 within an energy window of 3.0 kcal mol−1 were performed by using the OPLS3 molecular mechanics force field. A total of 19 conformers were obtained. The conformers were then further optimized with the software package Gaussian 09 at the B3LYP/6-311G(d, p) level. The dominant conformers were evaluated according to the optimization energy and the populations were provided in Table S1. And then the 60 lowest electronic transitions for the obtained dominant conformers were calculated using time-dependent density functional theory (TD-DFT) methods at the CAM-B3LYP/6-311G(d, p) level. ECD spectra of the conformers were simulated using a Gaussian function. The overall theoretical ECD spectra were obtained according to the Boltzmann weighting of each dominant conformer.28
Cytotoxicity assays. MTT assays were performed as previously described.24 Briefly, cells were seeded into 96-well plates at a density of 5 × 103 cells per well for 24 h and were exposed to different concentrations of test compounds. After incubation for 72 h, cells were stained with 25 µL of MTT solution (5 mg per mL) for 25 min. Finally, the mixture of medium and MTT solution was removed, and 75 µL of DMSO was added to dissolve formazan crystals. Absorbance of each well was measured at 544 nm (test wavelength) and 690 nm (background) using the multi-mode microplate reader. Background was subtracted from the absorbance of each well. Cisplatin was used as the positive control three duplicate wells were used for each concentration, and all the tests were repeated three times.
Antimicrobial assay. The antibacterial activities against two aquatic bacteria Vibrio alginolyticus ATCC 33787, and V. harveyi ATCC 33842, were carried out by a serial dilution technique using 96-well microtiter plates.25 The final concentrations of the test compound in the well were 64, 32, 16, 8, 4, 2, 1, and 0.5 µg per mL. Chloramphenicol was used as the positive control.

Conclusions

In summary, two new macrolides, penicurvularins A and B (1 and 2), and the three known compounds 5-methoxycurvularin, curvularin, and dehydrocurvularin (35) were isolated from cultures of the ascomycete fungus Alternaria sp. Their structures were elucidated based on NMR spectroscopic data and electronic circular dichroism (ECD) calculations. Compound 1 represents the first example of curvularin derivative featuring a unique 5-methylfuran-2-yl-methyl and a furan moiety. Compound 2 is structurally related to 5-methoxycurvularin (3), but differs by having a hydroxyl group at C-4. Compounds 1 and 5 are active against aquatic pathogenic bacteria Vibrio alginolyticus and V. harveyi with MIC values ranging from 4 to 8 µg mL−1, while compound 5 is cytotoxic against tumor cell lines Huh7, 786-O, and 763 with IC50 values of 11.6, 10.7, and 3.5 µM, respectively.

Conflicts of interest

The authors declare no conflict interest.

Data availability

The authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary information (SI). Supplementary information: UV, IR, HRESIMS, NMR spectra of compounds 1; ECD calculations of compounds 1. See DOI: https://doi.org/10.1039/d5ra09998f.

Acknowledgements

We gratefully acknowledge financial support from the Jiangsu Food & Pharmaceutical Science College (302320230555) and Jiangsu Province Shuangchuang Doctor Program (JSSCBS0573).

Notes and references

  1. A. Evidente, Nat. Prod. Rep., 2022, 39, 1591–1621 RSC.
  2. C. X. Wang, R. Ding, S. T. Jiang, J. S. Tang, D. Hu, G. D. Chen, F. Lin, K. Hong, X. S. Yao and H. Gao, J. Nat. Prod., 2016, 79, 2446–2454 CrossRef CAS PubMed.
  3. P. R. Koliye, A. N Bissoue, E. N. M. Mouelle, S. K. Nguikwie, C. V. Z. Owona, V. E. Simons, S. H. Akone, L. M. Meva'a, R. Kalscheuer and Z. Naturforsch, C J. Biosci., 2024, 79, 371–376 CAS.
  4. I. Pérez-Victoria, D. Oves-Costales, R. Lacret, J. Martín, M. Sánchez-Hidalgo, C. Díaz, B. Cautain, F. Vicente, O. Genilloud and F. Reyes, Org. Biomol. Chem., 2019, 17, 2954–2971 RSC.
  5. Z. Yu, L. Wang, J. Yang, F. Zhang, Y. Sun, M. Yu, Y. Yan, Y. Ma and S. Huang, Tetrahedron Lett., 2016, 57, 1375–1378 Search PubMed.
  6. K. Umeda, A. Iwasaki, R. Taguchi, N. Kurisawa, G. Jeelani, T. Nozaki and K. Suenaga, J. Nat. Prod., 2023, 86, 2529–2538 Search PubMed.
  7. F. H. Al-Awadhi, S. Kokkaliari, R. Ratnayake, V. J. Paul and H. Luesch, J. Nat. Prod., 2024, 87, 2355–2365 Search PubMed.
  8. Y. Wu, Z. Zhang, Y. Zhong, J. Huang, X. Li, J. Jiang, Y. Deng, L. Zhang and F. He, RSC Adv., 2017, 7, 40015–40019 Search PubMed.
  9. J. S. An, H. J. Lim, J. Y. Lee, Y. J. Jang, S. J. Nam, S. K. Lee and D. C. Oh, J. Nat. Prod., 2022, 85, 936–942 Search PubMed.
  10. F. R. Heilman, W. E. Herrell, W. E. Wellman and J. E. Geraci, Proc. Staff Meet Mayo Clin., 1952, 27, 285–304 Search PubMed.
  11. K. D. Lenz, K. E. Klosterman, H. Mukundan and J. Z. Kubicek-Sutherland, Toxins, 2021, 13, 347 Search PubMed.
  12. C. A. Miller, J. M. Ho, S. E. Parks and M. R. Bennett, ACS Synth. Biol., 2021, 10, 258–264 Search PubMed.
  13. K. Arai, B. J. Rawlings, Y. Yoshizawa and J. C. Vederas, J. Am. Chem. Soc., 1989, 111, 3391–3399 Search PubMed.
  14. J. Zhan, E. M. K. Wijeratne, C. J. Seliga, J. Zhang, E. E. Pierson, L. S. Pierson III, H. D. Vanetten and A. A. L. Gunatilaka, J. Antibiot., 2004, 57, 341–344 Search PubMed.
  15. A. H. Aly, A. Debbab, C. Clements, R. Edrada-Ebel, B. Orlikova, M. Diederich, V. Wray, W. Lin and P. Proksch, Bioorgan. Med. Chem., 2011, 19, 414–421 CrossRef CAS PubMed.
  16. B. J. Rawlings, Nat. Prod. Rep., 2001, 18, 190–227 Search PubMed.
  17. E. Li, F. Zhang, S. Niu, X. Liu, G. Liu and Y. Che, Org. Lett., 2012, 14, 3320–3323 Search PubMed.
  18. J. Zhang, L. Liu, B. Wang, Y. Zhang, L. Wang, X. Liu and Y. Che, J. Nat. Prod., 2015, 78, 3058–3066 Search PubMed.
  19. X. Hou, Y. Xu, S. Zhu, Y. Zhang, L. Guo, F. Qiu and Y. Che, RSC Adv., 2020, 10, 15622–15628 RSC.
  20. Z. Deng, A. Deng, D. Luo, D. Gong, K. Zou, Y. Peng and Z. Guo, Nat. Prod. Commun., 2015, 10, 1277–1278 Search PubMed.
  21. E. L. Ghisalberti, D. C. R. Hockless, C. Y. Rowland and A. H. White, Aust. J. Chem., 1993, 46, 571–575 Search PubMed.
  22. E. L. Ghisalerti and C. Y. Rowland, J. Nat. Prod., 1993, 56, 2175–2177 CrossRef.
  23. S. Zhu, F. Ren, Z. Guo, J. Liu, X. Liu, G. Liu and Y. Che, J. Nat. Prod., 2019, 82, 462–468 Search PubMed.
  24. N. Zhang, Y. Chen, R. Jiang, E. Li, X. Chen, Z. Xi, Y. Guo, X. Liu, Y. Zhou, Y. Che and X. Jiang, Autophagy, 2011, 7, 598–612 Search PubMed.
  25. C. G. Pierce, P. Uppuluri, A. R. Tristan, F. L. Wormley Jr, E. Mowat, G. Ramage and J. L. Lopez-Ribot, Nat. Protoc., 2008, 3, 1494–1500 Search PubMed.
  26. R. R. Banala, S. K. Vemuri, S. Ev, G. R. Av and S. Gpv, Asian Spine J., 2021, 15, 143–154 Search PubMed.
  27. Z. Fan, X. Zhao, M. Li, H. Wang and R. Huang, Chem. Biodivers., 2025, 22, e01583 CrossRef CAS PubMed.
  28. M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. Montgomery Jr, J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, O. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski and D. J. Fox, Gaussian 09, Rev D.01, Gaussian, Inc.: Wallingford, CT, 2009 Search PubMed.

This journal is © The Royal Society of Chemistry 2026
Click here to see how this site uses Cookies. View our privacy policy here.